POTENTIALS OF ANGIOTENSIN II RECEPTOR BLOCKERS IN HALTING THE PROGRESSION OF RENAL TRANSPLANT NEPHROPATHY


Cite item

Full Text

Abstract

The article presents pathogenical and clinical justification of administration of angiotensin II receptor blockers, in particular valsartan, in recipients of kidney transplant for the purpose to prevention and inhibition of progression its chronic rejection

About the authors

M L Maksimov

References

  1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002;39:S1-S000.
  2. Смирнов А.В., Есаян А.М., Каюков И.Г. Хроническая болезнь почек: на пути к единству представлений // Нефрология. 2002. № 6 (4). С. 11-17.
  3. Ким И.Г., Стенина И.И., Ильинский И.М. и др. Отдаленные результаты трансплантации почки и факторы риска хронической нефропатии отторжения // Нефрология и диализ. 1999. № 1(1). С. 32-36.
  4. Столяревич Е.С. Хроническая трансплантационная нефропатия: механизмы развития и факторы прогрессирования // Нефрология и диализ. 2002. № 4(1). С. 24-30.
  5. Шумаков В.И., Ильинский И.М., Белецкая Л.В. и др. Гистологические и иммуноморфологические исследования хронического отторжения трансплантированных почек // Вестник трансплантологии и искусственных органов. 2000. № 3. С. 30-34.
  6. Томилина Н.А., Балакирев Э.М., Ким И.Г. Отдаленные результаты трансплантации почки // Вестник трансплантологии и искусственных органов. 2001. № 3-4. С. 65-75.
  7. Mange KC, Cizman B, Joffe M, et al. Arterial Hypertension and Renal Allograft Survival. JAMA 2000;283:633-38.
  8. Mange KC, Feldman HI, Joffe MM, et al. Bloom Blood Pressure and the Survival of Renal Allografts from Living Donors J Am Soc Nephrol 2004;15:187-93.
  9. Al-Wakeel J, Mitwalli AH, Tarif N, et al. Living unrelated renal transplant: outcome and issues. Saudi J Kidney Dis Transpl 2000;11(4):553-58.
  10. Massy ZA, Guijarro C, Wiederkehr MR, et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996;49(2):518-24.
  11. Curtis JJ. Treatment of hypertension in renal allograft patients: Does drug selection make a difference? Kidney Int 1997;52(Suppl. 63):S75-S77.
  12. Johnson CA. Clinical Practice Guidelines for Chronic Kidney Disease in Adults: Part I. Am Pham Physician 2004;70(5):869-76.
  13. Sanders CE, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int 1995;52(Suppl.):S43-S47.
  14. Luke RG. Pathophysiology and treatment of posttransplant hypertension. J Am Soc Nephrol 1991;2 (Suppl 1):S37-S44.
  15. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998;53:217-22.
  16. Vianello A, Mastrosimone S, Calconi G, et al. The role of hypertension as a damaging factor for kidney grafts under cyclosporine therapy. Am J Kidney Dis 1993;21(5 Suppl. 2):79-83.
  17. Cosio F, Falkenhain ME, Pesavento TE, et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997;29: 419-27.
  18. Ritz E. Hypertonie und Niere. Arzneim.-Forsch. Drug Res 1997;47(11):1297-301.
  19. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001;161:1207-16.
  20. Ponticelli C. Renal transplantation 2004: where do we stand today? Nephrol Dial Transplant 2004;19(12):2937-47.
  21. Roodnat J, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001;72:438-42.
  22. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, et al. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004;19:III47-III51.
  23. Sancho A, Gavela E, Avila A, et al. Risk factors and prognosis for proteinuria in renal transplant recipients. Transplant Proc 2007;39(7):2145-47.
  24. Pascual M, Theruvah Т, Tolkoff-Rubin N, et al. Strategies to improve long-term outcome after renal transplantation. N Engl J Med 2002;346(8):580-90.
  25. Fogo AB. Progression versus regression of chronic kidney disease. Nephrol Dial Transplant 2006;21(2):281-84.
  26. Fogo AB. Progression and potential regression of glomerulosclerosis. Nephrology Forum Kidney Int 2001;59:804-19.
  27. Багдасарян А.Р., Столяревич Е.С., Ким И.Г. и др. Влияние эналаприла на скорость прогрессирования хронической трансплантационной нефропатии // Нефрология и диализ. 2003. № 5(1). С. 17-22.
  28. Walls J. Role of proteinuria in progressive renal disease. Am J Kidney Dis 2001;37(Suppl. 2):13-20.
  29. Modlin C, Goldfarb D, Novick AC. Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation. Word J Urol 1996;14(4):256-64.
  30. Tall M, Brenner BB. Renoprotective benefits of RAS inhibition: from ACEi to angiotensin II antagonists. Kidney Int 2000;57:1803-17.
  31. Томилина Н.А., Багдасарян А. Р. Механизмы нефросклероза и фармакологическая ингибиция внутри почечной ренин-ангиотензиновой системы как основа нефропротективной стратегии при хронических заболеваниях нативных почек и почечного трансплантата (Обзор литературы) // Нефрология и диализ. 2004. № 6(3). С. 21-26.
  32. Rossing P, Parving HH, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction? Nephrol Dial Transplant 2006;21(9):2354-57.
  33. Сидоренко Б.А., Преображенский Д.В. Блокаторы АТ1-ангиотензиновых рецепторов. М., 2001.
  34. Bauer JH, Reams GP. The angiotensin 11 type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995;155:1361-68.
  35. De Leeuw PW. How do angiotensin II receptor antagonists affect blood pressure? Am J Cardiol 1999;84(Suppl. 2A):5K-6K.
  36. Карпов Ю.А. Блокаторы ангиотензиновых рецепторов: обоснование нового направления терапии в современной кардиологии // РМЖ. 2000. № 5. С. 214-218.
  37. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure - independent effect. Circulation 2002;106:672-78.
  38. Wolf G. The Renin-Angiotensin System and Progression of Renal Disease. In: Contributions to Nephrology. Editor G. Wolf. 2001.
  39. Weinberg AJ, Zappe DH, Ashton M, et al. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004;24:340-45.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies